Magnolia Wealth Management LLC acquired a new stake in Pfizer Inc. (NYSE:PFE – Get Rating) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 127,145 shares of the biopharmaceutical company’s stock, valued at approximately $6,589,000. Pfizer makes up approximately 0.5% of Magnolia Wealth Management LLC’s investment portfolio, making the stock its 14th biggest holding.
Other large investors have also modified their holdings of the company. Birinyi Associates Inc. lifted its holdings in shares of Pfizer by 3.4% during the first quarter. Birinyi Associates Inc. now owns 6,000 shares of the biopharmaceutical company’s stock worth $311,000 after buying an additional 200 shares during the last quarter. Curbstone Financial Management Corp raised its stake in Pfizer by 0.3% during the 1st quarter. Curbstone Financial Management Corp now owns 65,901 shares of the biopharmaceutical company’s stock valued at $3,412,000 after purchasing an additional 200 shares during the last quarter. Douglass Winthrop Advisors LLC raised its position in shares of Pfizer by 0.3% during the first quarter. Douglass Winthrop Advisors LLC now owns 57,804 shares of the biopharmaceutical company’s stock valued at $2,993,000 after buying an additional 200 shares during the last quarter. Oak Harbor Wealth Partners LLC raised its position in shares of Pfizer by 0.3% during the first quarter. Oak Harbor Wealth Partners LLC now owns 70,464 shares of the biopharmaceutical company’s stock valued at $3,648,000 after buying an additional 203 shares during the last quarter. Finally, JSF Financial LLC raised its position in shares of Pfizer by 1.4% during the first quarter. JSF Financial LLC now owns 14,336 shares of the biopharmaceutical company’s stock valued at $742,000 after buying an additional 203 shares during the last quarter. 67.90% of the stock is owned by hedge funds and other institutional investors.
Pfizer Stock Performance
Shares of NYSE:PFE opened at $46.19 on Wednesday. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.20 and a current ratio of 1.42. The firm has a market cap of $259.23 billion, a PE ratio of 9.04, a price-to-earnings-growth ratio of 0.59 and a beta of 0.70. Pfizer Inc. has a twelve month low of $40.94 and a twelve month high of $61.71. The business has a fifty day moving average of $49.41 and a 200-day moving average of $50.46.
Pfizer (NYSE:PFE – Get Rating) last posted its quarterly earnings data on Thursday, July 28th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.95 by $0.09. Pfizer had a net margin of 28.92% and a return on equity of 43.18%. The firm had revenue of $27.74 billion during the quarter, compared to analysts’ expectations of $26.20 billion. During the same quarter last year, the company posted $1.07 EPS. The company’s quarterly revenue was up 46.8% compared to the same quarter last year. On average, equities research analysts predict that Pfizer Inc. will post 6.54 EPS for the current fiscal year.
Pfizer Dividend Announcement
The company also recently declared a quarterly dividend, which was paid on Tuesday, September 6th. Stockholders of record on Wednesday, June 29th were paid a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a dividend yield of 3.46%. The ex-dividend date of this dividend was Thursday, July 28th. Pfizer’s dividend payout ratio (DPR) is presently 31.31%.
Wall Street Analysts Forecast Growth
Several research firms have commented on PFE. Barclays set a $50.00 price target on Pfizer in a report on Thursday, September 1st. SVB Leerink cut their target price on Pfizer from $55.00 to $53.00 and set a “market perform” rating for the company in a research note on Friday, July 29th. JPMorgan Chase & Co. set a $57.00 target price on Pfizer in a research note on Tuesday, June 28th. The Goldman Sachs Group set a $50.00 price objective on shares of Pfizer in a research note on Thursday, September 1st. Finally, Berenberg Bank set a $44.00 price objective on shares of Pfizer in a research note on Wednesday. Nine investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Pfizer presently has an average rating of “Moderate Buy” and a consensus price target of $57.00.
Pfizer Profile
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women’s health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.
Further Reading
Receive News & Ratings for Pfizer Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Pfizer and related companies with MarketBeat.com’s FREE daily email newsletter.
